Contributing to the health of all people around the world by providing specialized blood cells using stem cell technology
The technology of regenerative medicine will enable mass production and stable supply of homogeneous and highly accurate “Specialized blood cells” dramatically improving the efficiency of infectious disease research and the efficacy and safety evaluation of pharmaceuticals and functional materials, and realize a new cell-based drug discovery platform.
We combine four cell-specific technologies: gene editing, differentiation induction, immortalization,
and integrated production to design specialized blood cells at will.
We induce differentiation into hematopoietic cells, change cells at will, and make it possible to provide homogeneous specialized cells in large quantities and in a stable manner based on immortalization and integrated production technologies.
Using this “cell design technology,”
we provide high-precision “immature blood cells” developed for the evaluation of functional materials for pharmaceuticals,
foods, cosmetics, etc.,
and “evaluation services” using these cells.
We sell immature blood cells that are homogeneous and highly accurate through regenerative medicine technology, SRIPs that enable safe infection evaluation and antibody-dependent enhanced infection (ADE) evaluation without the use of live viruses, and evaluation kits that enable immediate cell-based evaluation.
We undertake screening tests for drug candidates and functional evaluation of materials using high-precision blood cell products. We can freely select and design blood cells and construct an evaluation system that meets your needs with the knowledge of our experts.
Please feel free to contact us.
We will conduct a brief interview with the person in charge and propose the best solution to solve your company’s issues.